Campbell B C, Lawrence J R, Sumner D J, Kelman A, Smith A, Elliott H L, Goldberg A
Pharmatherapeutica. 1980;2(7):475-80.
The pharmacokinetics of iron poly (sorbitol-gluconic acid) complex (IPSG) were studied following a single intramuscular injection of 59Fe-labelled IPSG to 4 iron deficient-patients. The results showed a more rapid uptake of iron from the site of injection than that reported with iron dextran while there was a lower urinary excretion than found with iron sorbitol citrate. A clinical study was carried out in 11 patients with iron deficiency anaemia. Patients were allocated at random to receive IPSG as either 250 mg or 500 mg elemental iron per week for 8 weeks. A satisfactory response to therapy was obtained with each regimen whether measured by an increase in haemoglobin concentration or in serum ferritin concentration. Few side-effects were encountered but discomfort and staining at the injection site was found on the higher dose schedule.
对4名缺铁患者单次肌内注射59Fe标记的聚(山梨醇 - 葡萄糖酸)铁络合物(IPSG)后,研究了其药代动力学。结果显示,与右旋糖酐铁相比,IPSG从注射部位的铁摄取更快,而尿排泄量低于柠檬酸山梨醇铁。对11名缺铁性贫血患者进行了一项临床研究。患者被随机分配,每周接受250毫克或500毫克元素铁的IPSG,持续8周。无论通过血红蛋白浓度增加还是血清铁蛋白浓度增加来衡量,每种治疗方案都获得了令人满意的治疗反应。几乎没有遇到副作用,但在高剂量方案中发现注射部位有不适和染色现象。